Date: 2013-09-03
Type of information: Series B financing round
Company: Acacia Pharma (UK)
Investors: Fidelity Biosciences (USA), Novo A/S (Denmark), Gilde Healthcare (The Netherlands), Lundbeckfond Ventures (Denmark)
Amount: £15 million (€17.7 million)
Funding type: series B financing round
Planned used: Acacia Pharma will use the proceeds to complete Phase III development of APD421 for the prevention of post-operative nausea & vomiting (PONV); to complete Phase II development of APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV); and to develop the commercial presentation of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.
Others: * On September 3, 2013, Acacia Pharma, a UK pharmaceutical company specialising in the development of drugs for supportive care, has announced it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Board of Acacia Pharma as Non-executive Directors.
Therapeutic area:
